Back to News
Dec 15, 2025 4:00 PM

Sanofi Expands Dren Bio Partnership With Potential $1.7 Billion Autoimmune Disease Collaboration

Dren Bio, a privately held, clinical-stage biotechnology company, has a new collaboration with Sanofi SA (NASDAQ:SNY). The new agreement is built on the existing relationship between the two companies, following Sanofi’s acquisition earlier this year of Dren Bio’s DR-0201 program for deep B-cell depletion.

• Sanofi shares are experiencing downward pressure. Why are SNY shares declining?

The collaboration covers the discovery and development of a next-generation B-cell depleting therapy for ...